Kiniksa Pharmaceuticals International, PLC Schedule 13G passive stakes

FMR LLC, along with Abigail P. Johnson, has reported a beneficial ownership of 14.8% in Kiniksa Pharmaceuticals International PL's Class A Common Stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting zero beneficial ownership in Kiniksa Pharmaceuticals International Plc following an internal realignment.

FMR LLC and its affiliates, including Abigail P. Johnson, have reported a 10.6% beneficial ownership stake in Kiniksa Pharmaceuticals International PL's Class A Common Stock.

The Vanguard Group has reported a 7.04% beneficial ownership stake in Kiniksa Pharmaceuticals International Plc common stock as of September 30, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 1.0% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc, totaling 418,151 common shares.

Rubric Capital Management LP and David Rosen have disclosed a beneficial ownership of 9.24% of Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.

Rubric Capital Management LP and David Rosen have disclosed a continued beneficial ownership of 8.05% of Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.4% beneficial ownership stake in Kiniksa Pharmaceuticals International, plc as of March 31, 2025.

Tang Capital Management, LLC and its affiliates, including Kevin Tang, have reported a passive beneficial ownership of 5.2% in Kiniksa Pharmaceuticals International, plc's Class A Ordinary Shares.

Fairmount Funds Management LLC and its affiliates have fully divested their 5.3% beneficial ownership in Kiniksa Pharmaceuticals International, plc, holding zero shares as of the filing date.